Nuvalent's cancer drug under FDA review, weeks after GSK closes $10.6B buyout on July 23, 2026 ALK gene Antineoplastic Agents Approved neladalkib Non-Small Cell Lung Carcinoma Nuvalent ROS1 gene SmithKline Beecham United States Food and Drug Administration zidesamtinib +
GSK to Acquire Nuvalent for $10.6 Billion, Marking Its Largest Oncology Push in a Decade on June 10, 2026 acquisition ALK Inhibitor Inhibitor Malignant neoplasm of lung neladalkib Neoplasms Nuvalent ROS1 gene SmithKline Beecham zidesamtinib +
Datar Cancer Genetics Announces US FDA Clearance for CellDx-Tissue on May 15, 2026 ALK gene CellDx-Tissue Clearance Comprehensive Datar Cancer Genetics DNA erbB-2 Receptor Genetic Profile NGS RET protein, human RNA ROS1 gene Solid Neoplasm United States Food and Drug Administration US +
Eisai Licenses Nuvation Bio's Taletrectinib for ROS1+ Lung Cancer in Europe and Asia on January 13, 2026 Eisai licensing agreement Malignant neoplasm of lung Non-Small Cell Lung Carcinoma Nuvation Bio ROS1 gene taletrectinib +